Skip to main content
Top
Published in: Clinical Rheumatology 1/2012

01-01-2012 | Original Article

Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren’s syndrome

Authors: Tetsutaro Kitagawa, Koichi Shibasaki, Shuji Toya

Published in: Clinical Rheumatology | Issue 1/2012

Login to get access

Abstract

Anti-SS-A/Ro antibody (SS-A) and anti-SS-B/La antibody (SS-B) are important serologic markers in the diagnostic criteria for Primary Sjögren’s syndrome (SS). Although anti-centromere antibody (ACA)-positive SS is frequently experienced, ACA is not included in these criteria. The purpose of this study was to identify the clinical features of ACA-positive SS and discuss the usefulness of ACA in diagnosing SS. Forty-five patients with SS were divided into the following three groups: SS-A only-positive group (n = 17), SS-A and SS-B both-positive group (n = 18), and ACA only-positive group (n = 10). As a control, 54 patients without SS who were negative for antinuclear antibodies were also evaluated. The following items were compared among groups: Saxon’s test, unstimulated whole salivary flow (UWSF), salivary gland scintigraphy (SGS), histopathologic examination of the minor salivary glands, Schirmer’s test, and fluorescein staining of the cornea. In the ACA only-positive group, Saxon’s test was 0.21 ± 0.26 g/2 min (mean ± SD) and UWSF was 0.16 ± 0.25 ml/10 min (mean ± SD), showing a significant decrease in salivary secretion (p < 0.05; vs. non-SS). On SGS, accumulation and disappearance of 99mTcO 4 were significantly decreased (p < 0.05; vs. non-SS). Histopathologic examination showed moderate or severe lymphocytic infiltration and tissue destruction in all cases, similar to that in the SS-A- and/or SS-B-positive groups. Schirmer’s test and fluorescein staining were positive in 60% and 80%, respectively. Impaired lacrimal secretion and keratoconjunctivitis sicca were similar to those in SS-A- and/or SS-B-positive groups. These results suggest that ACA is an autoantibody reflecting impairment in the salivary and lacrimal glands and may be a useful serologic marker for SS.
Literature
1.
go back to reference Sjögren H (1933) Zur kenntnis der keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol (Copenhagen). Suppl II:1–151. Sjögren H (1933) Zur kenntnis der keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol (Copenhagen). Suppl II:1–151.
2.
go back to reference Ramos-Casals M, Nardi N, Brito-Zerón P, Aguiló S, Gil V, Delgado G, Bové A, Font J (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35:312–321PubMedCrossRef Ramos-Casals M, Nardi N, Brito-Zerón P, Aguiló S, Gil V, Delgado G, Bové A, Font J (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35:312–321PubMedCrossRef
3.
go back to reference Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631PubMedCrossRef Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631PubMedCrossRef
4.
go back to reference Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625PubMedCrossRef Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625PubMedCrossRef
5.
go back to reference Frizler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRef Frizler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRef
6.
go back to reference Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (1984) The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700–706PubMed Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (1984) The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700–706PubMed
7.
go back to reference Powell FC, Schroeter AL, Dickson ER (1987) Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 62:75–82PubMed Powell FC, Schroeter AL, Dickson ER (1987) Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 62:75–82PubMed
8.
go back to reference Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297–301PubMedCrossRef Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297–301PubMedCrossRef
9.
go back to reference Caramaschi P, Biasi D, Carletto A, Manzo T, Randon M, Zeminian S, Bambara LM (1997) Sjögren’s syndrome with anticentromere antibodies. Rev Rheum Engl Ed 64:785–788 Caramaschi P, Biasi D, Carletto A, Manzo T, Randon M, Zeminian S, Bambara LM (1997) Sjögren’s syndrome with anticentromere antibodies. Rev Rheum Engl Ed 64:785–788
10.
go back to reference Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsay GJ (2006) Anti-CENP-H antibodies in patients with Sjogren’s syndrome. Rheumatol Int 26:298–303PubMedCrossRef Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsay GJ (2006) Anti-CENP-H antibodies in patients with Sjogren’s syndrome. Rheumatol Int 26:298–303PubMedCrossRef
11.
go back to reference Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM (2010) Anticentromere antibody positive Sjögren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther 12:R47PubMedCrossRef Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM (2010) Anticentromere antibody positive Sjögren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther 12:R47PubMedCrossRef
12.
go back to reference Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y (2005) Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 32:1488–1494PubMed Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y (2005) Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 32:1488–1494PubMed
13.
go back to reference Katano K, Kawano M, Koni I, Sugai S, Muro Y (2001) Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol 28:2238–2244PubMed Katano K, Kawano M, Koni I, Sugai S, Muro Y (2001) Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol 28:2238–2244PubMed
14.
go back to reference Takada K, Suzuki K, Okada M, Nakashima M, Ohsuzu F (2006) Salivary production rates fall with age in subjects having anticentromere, anti-Ro, and/or anti-La antibodies. Scand J Rheumatol 35:23–28PubMedCrossRef Takada K, Suzuki K, Okada M, Nakashima M, Ohsuzu F (2006) Salivary production rates fall with age in subjects having anticentromere, anti-Ro, and/or anti-La antibodies. Scand J Rheumatol 35:23–28PubMedCrossRef
15.
go back to reference Yan SM, Zeng XF, Zhao Y, Dong Y (2008) A clinical analysis of primary Sjögren’s syndrome with anticentromere antibodies. Zhonghua Nei ke Za Zhi 47:296–299PubMed Yan SM, Zeng XF, Zhao Y, Dong Y (2008) A clinical analysis of primary Sjögren’s syndrome with anticentromere antibodies. Zhonghua Nei ke Za Zhi 47:296–299PubMed
16.
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopolos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopolos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558PubMedCrossRef
17.
go back to reference Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K (2004) Revised Japanese criteria for Sjogren’s syndrome (1999): availability and validity. Mod Rheumatol 14:425–434CrossRef Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K (2004) Revised Japanese criteria for Sjogren’s syndrome (1999): availability and validity. Mod Rheumatol 14:425–434CrossRef
18.
go back to reference Toyama M, Tsuchimochi M (2004) Salivary gland scintigraphy in patients with Sjögren’s syndrome. Dental Radiol 44:53–58 Toyama M, Tsuchimochi M (2004) Salivary gland scintigraphy in patients with Sjögren’s syndrome. Dental Radiol 44:53–58
19.
go back to reference Greenspan JS, Daniels TE, Talal N, Sylvester RA (1974) The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 37:217–229PubMedCrossRef Greenspan JS, Daniels TE, Talal N, Sylvester RA (1974) The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 37:217–229PubMedCrossRef
20.
go back to reference Maeda N, Yamaji K, Kimura K, Kim Y, Tsuda H, Hirose S, Hashimoto H (2005) Analysis of clinical questionnaire of Tokyo Metropolitan Government for Sjogren’s syndrome. Jpn J Clin Immunol 28:398–406CrossRef Maeda N, Yamaji K, Kimura K, Kim Y, Tsuda H, Hirose S, Hashimoto H (2005) Analysis of clinical questionnaire of Tokyo Metropolitan Government for Sjogren’s syndrome. Jpn J Clin Immunol 28:398–406CrossRef
21.
go back to reference Lundström IM, Lundström FD (1995) Subjective and clinical oral symptoms in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 13:725–731PubMed Lundström IM, Lundström FD (1995) Subjective and clinical oral symptoms in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 13:725–731PubMed
22.
go back to reference Pedersen AM, Reibel J, Nauntofte B (1999) Primary Sjögren’s syndrome (pSS): subjective symptoms and salivary findings. J Oral Pathol Med 28:303–311PubMedCrossRef Pedersen AM, Reibel J, Nauntofte B (1999) Primary Sjögren’s syndrome (pSS): subjective symptoms and salivary findings. J Oral Pathol Med 28:303–311PubMedCrossRef
23.
go back to reference Márton K, Boros I, Varga G, Zelles T, Fejérdy P, Zeher M, Nagy G (2006) Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren’s syndrome. Oral Dis 12:480–486PubMedCrossRef Márton K, Boros I, Varga G, Zelles T, Fejérdy P, Zeher M, Nagy G (2006) Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren’s syndrome. Oral Dis 12:480–486PubMedCrossRef
24.
go back to reference Pedersen AM, Reibel J, Nordgarden H, Bergem HO, Jensen JL, Nauntofte B (1999) Primary Sjögren’s syndrome: salivary gland function and clinical oral findings. Oral Dis 5:128–138PubMedCrossRef Pedersen AM, Reibel J, Nordgarden H, Bergem HO, Jensen JL, Nauntofte B (1999) Primary Sjögren’s syndrome: salivary gland function and clinical oral findings. Oral Dis 5:128–138PubMedCrossRef
25.
go back to reference Aung W, Murata Y, Ishida R, Takahashi Y, Okada N, Shibuya H (2001) Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren’s syndrome. J Nucl Med 42:38–43PubMed Aung W, Murata Y, Ishida R, Takahashi Y, Okada N, Shibuya H (2001) Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren’s syndrome. J Nucl Med 42:38–43PubMed
26.
go back to reference Tsujii H, Furudate M, Irie G (1980) Effects of radiotherapy on the salivary gland as measured by 99mTcO 4 − . Nippon Igaku Hoshasen Gakkai Zasshi 40:485–493PubMed Tsujii H, Furudate M, Irie G (1980) Effects of radiotherapy on the salivary gland as measured by 99mTcO 4 . Nippon Igaku Hoshasen Gakkai Zasshi 40:485–493PubMed
27.
go back to reference Adams BK, Al Attia HM, Parkar S (2003) Salivary gland scintigraphy in Sjögren’s syndrome: are quantitative indices the answer? Nucl Med Commun 24:1011–1016PubMedCrossRef Adams BK, Al Attia HM, Parkar S (2003) Salivary gland scintigraphy in Sjögren’s syndrome: are quantitative indices the answer? Nucl Med Commun 24:1011–1016PubMedCrossRef
28.
go back to reference Hermann GA, Vivino FB, Shnier D, Krumm RP, Mayrin V, Shore JB (1998) Variability of quantitative scintigraphic salivary indices in normal subjects. J Nucl Med 39:1260–1263PubMed Hermann GA, Vivino FB, Shnier D, Krumm RP, Mayrin V, Shore JB (1998) Variability of quantitative scintigraphic salivary indices in normal subjects. J Nucl Med 39:1260–1263PubMed
29.
go back to reference Aung W, Yamada I, Umehara I, Ohbyashi N, Yoshino N, Shibuya H (2000) Sjögren’s syndrome: comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography. J Nucl Med 41:257–262PubMed Aung W, Yamada I, Umehara I, Ohbyashi N, Yoshino N, Shibuya H (2000) Sjögren’s syndrome: comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography. J Nucl Med 41:257–262PubMed
30.
go back to reference Kohn WG, Ship JA, Atkinson JC, Patton LL, Fox PC (1992) Salivary gland 99m-Tc-scintigraphy: a grading scale and correlation with major salivary gland flow rates. J Oral Pathol Med 21:70–74PubMedCrossRef Kohn WG, Ship JA, Atkinson JC, Patton LL, Fox PC (1992) Salivary gland 99m-Tc-scintigraphy: a grading scale and correlation with major salivary gland flow rates. J Oral Pathol Med 21:70–74PubMedCrossRef
31.
go back to reference Shizukuishi K, Nagaoka S, Kinno Y, Saito M, Takahashi N, Kawamoto M, Abe A, Jin L, Inoue T (2003) Scoring analysis of salivary gland scintigraphy in patients with Sjögren’s syndrome. Ann Nucl Med 17:627–631PubMedCrossRef Shizukuishi K, Nagaoka S, Kinno Y, Saito M, Takahashi N, Kawamoto M, Abe A, Jin L, Inoue T (2003) Scoring analysis of salivary gland scintigraphy in patients with Sjögren’s syndrome. Ann Nucl Med 17:627–631PubMedCrossRef
32.
go back to reference Mita S, Kohno M, Matsuoka Y, Matsuoka Y, lrimajiri S, Fujimori I, Fukuda J (1981) Diagnostic availability of RI-sialography in Sjogren’s syndrome. Ryumachi 21:305–316 Mita S, Kohno M, Matsuoka Y, Matsuoka Y, lrimajiri S, Fujimori I, Fukuda J (1981) Diagnostic availability of RI-sialography in Sjogren’s syndrome. Ryumachi 21:305–316
33.
go back to reference Sugihara T, Yoshimura Y (1988) Scintigraphic evaluation of the salivary glands in patients with Sjögren’s syndrome. Int J Oral Maxillofac Surg 17:71–75PubMedCrossRef Sugihara T, Yoshimura Y (1988) Scintigraphic evaluation of the salivary glands in patients with Sjögren’s syndrome. Int J Oral Maxillofac Surg 17:71–75PubMedCrossRef
34.
go back to reference Vinagre F, Santos MJ, Prata A, da Silva JC, Santos AI (2009) Assessment of salivary gland function in Sjögren’s syndrome: the role of salivary gland scintigraphy. Autoimmun Rev 8:672–676PubMedCrossRef Vinagre F, Santos MJ, Prata A, da Silva JC, Santos AI (2009) Assessment of salivary gland function in Sjögren’s syndrome: the role of salivary gland scintigraphy. Autoimmun Rev 8:672–676PubMedCrossRef
35.
go back to reference Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T, Nishinarita S, Hosokawa Y, Horie T, Obara T (1992) Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren’s syndrome. Am J Med 92:134–140PubMedCrossRef Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T, Nishinarita S, Hosokawa Y, Horie T, Obara T (1992) Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren’s syndrome. Am J Med 92:134–140PubMedCrossRef
36.
go back to reference Bernstein RM, Callender ME, Neuberger JM, Hughes GR, Williams R (1982) Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 41:612–614PubMedCrossRef Bernstein RM, Callender ME, Neuberger JM, Hughes GR, Williams R (1982) Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 41:612–614PubMedCrossRef
37.
go back to reference Makinen D, Fritzler M, Davis P, Sherlock S (1983) Anticentromere antibody in primary biliary cirrhosis. Arthritis Rheum 26:914–917PubMedCrossRef Makinen D, Fritzler M, Davis P, Sherlock S (1983) Anticentromere antibody in primary biliary cirrhosis. Arthritis Rheum 26:914–917PubMedCrossRef
38.
go back to reference Chan HL, Lee YS, Hong HS, Kuo TT (1994) Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19:298–302PubMedCrossRef Chan HL, Lee YS, Hong HS, Kuo TT (1994) Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19:298–302PubMedCrossRef
39.
go back to reference Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K (2007) Primary biliary cirrhosis(PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol 26:596–600PubMedCrossRef Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K (2007) Primary biliary cirrhosis(PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol 26:596–600PubMedCrossRef
40.
go back to reference Ford AL, Kurien BT, Harley JB, Scofield RH (1998) Anti-centromere autoantibody in a patient evolving from a lupus/Sjögren’s overlap to the CREST variant of scleroderma. J Rheumatol 25:1419–1424PubMed Ford AL, Kurien BT, Harley JB, Scofield RH (1998) Anti-centromere autoantibody in a patient evolving from a lupus/Sjögren’s overlap to the CREST variant of scleroderma. J Rheumatol 25:1419–1424PubMed
41.
go back to reference Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, Rosen A, Casciola-Rosen L (2006) Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis 65:1028–1032PubMedCrossRef Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, Rosen A, Casciola-Rosen L (2006) Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis 65:1028–1032PubMedCrossRef
Metadata
Title
Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren’s syndrome
Authors
Tetsutaro Kitagawa
Koichi Shibasaki
Shuji Toya
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1789-z

Other articles of this Issue 1/2012

Clinical Rheumatology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.